Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 17,73 € (+108,34 %). La médiane est de 17,73 € (+108,34 %).
| Acheter |
7 |
| Conserver |
1 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
BrainsWay beats revenue forecasts in Q2 2026 and raises full-year outlook
BrainsWay reported revenue of $17.1 million in Q2 2026, beating analysts’ estimate of $16.31 million; adjusted earnings per share were $0.07, in line with expectations. The company raised its 2026 revenue guidance to $68–70 million and recorded revenue growth of 35% year over year along with more than a fourfold increase in operating income. Gross margin remained steady at 75%, adjusted EBITDA was positive for the twelfth consecutive quarter, and the installed system base rose to around 1,950 units. Management cites strong demand for Deep TMS and the SWIFT protocol, as well as reimbursements covering about 57 million insured people, as drivers. » Plus sur de.investing.com
BrainsWay invests $3 million in Radial Health
BrainsWay has acquired a $3 million minority stake in Radial Health as part of a Series A financing round. Radial operates a network of brain-medicine clinics and develops clinical infrastructure, reimbursement tools, and an AI-supported decision platform for non-invasive therapies such as Deep TMS. The capital will be used to expand clinical presence, strengthen the technology platform and evaluate M&A opportunities; BrainsWay describes the investment as part of a strategy to acquire minority stakes in mental health care providers. » Plus sur de.investing.com
BrainsWay: US insurers allow psychiatric nurse practitioners to provide TMS treatment
A growing number of US insurers, including Optum/United Behavioral Health, have allowed psychiatric nurse practitioners in full-practice states since the end of 2025 to prescribe, supervise and administer transcranial magnetic stimulation (TMS) for commercial plans covering about 34.8 million enrollees. Other payers and providers such as First Coast, National Government Services, Novitas, the VA and TRICARE West have introduced similar reimbursement models, subject to regulatory requirements. BrainsWay sees this as an opportunity to improve access to deep TMS and shorten waiting times; the stock reacted positively and is trading near its 52-week high after a 258% gain last year. » Plus sur de.investing.com
BrainsWay invests additional $6 million in Neurolief after FDA premarket clearance
BrainsWay closes a milestone-based convertible note of $6 million as a second tranche for Neurolief after Neurolief received FDA premarket clearance for the Proliv™Rx system. With this, BrainsWay has invested a total of $11 million in Neurolief; a third tranche of up to $5 million is possible if a revenue-based target is met. BrainsWay also holds a purchase option on all outstanding shares of Neurolief, with the price tied to a fixed company valuation or a revenue multiple. Parallel to the financing, Neurolief is expanding provider access by adding an authorized distributor to the U.S. Department of Veterans Affairs supplier list. » Plus sur de.investing.com
BrainsWay: Highmark plans expanded reimbursement for accelerated Deep‑TMS protocol
Highmark Blue Cross Blue Shield has issued a draft policy to expand reimbursement for BrainsWay’s accelerated SWIFT‑Deep‑TMS protocol for adolescents and adults with major depressive disorder. After a public comment period, the rule is expected to take effect in February 2026 and covers a five‑times‑daily, 10‑minute program over six days plus follow‑up sessions (38 sessions in total). The FDA approved the protocol in September 2025; data showed a response rate of 87.8% and a remission rate of 78.0%, prompting BrainsWay to anticipate broader market acceptance. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 15,89 M | 37,99 % |
| Bénéfice brut | 12,38 M | 42,96 % |
| Bénéfice net | 1,95 M | 45,79 % |
| EBITDA | 2,68 M | 13,12 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 360,6 M € |
Nombre d'actions | 39,22 M |
Plus haut/bas sur 52 semaines | 15,82 € - 4,58 € |
| Dividendes | Non |
Bêta | 0,15 |
Ratio P/E | 38,94 |
Ratio PEG | 0,62 |
Ratio P/B | 4,90 |
Ratio P/S | 5,83 |
Profil de l'entreprise
Brainsway Ltd. développe et commercialise des traitements de neurostimulation non invasifs pour les troubles de la santé mentale aux États-Unis, en Europe, en Israël et à l'international. Elle propose la technologie de plateforme de stimulation magnétique transcrânienne profonde pour le traitement de la dépression majeure, de la dépression anxieuse, des troubles obsessionnels compulsifs, de la dépendance au tabac, des troubles bipolaires, des troubles de stress post-traumatique, de la schizophrénie, de la maladie d'Alzheimer, de l'autisme, des douleurs chroniques, de la sclérose en plaques, de la rééducation après un AVC et de la maladie de Parkinson. L'entreprise sert principalement des médecins, des hôpitaux et des centres médicaux dans le domaine de la psychiatrie. Brainsway Ltd. a été fondée en 2003 et son siège social se situe à Jérusalem, en Israël.
| Nom | BrainsWay (ADR) |
| PDG | Hadar Levy |
| Siège social | Jerusalem,
jm Israël |
| Site web | |
| Secteur | Santé |
| Industrie | Équipements et fournitures médicaux |
| Introduction en bourse | 17/12/2018 |
| Employés | 129 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | BWAY |